Parotid gland cancer treatment with targeted therapy

As with any other type of tumor, parotid gland cancer relies on a supply of certain chemical substances (proteins, organic acids, etc. ) to grow and keep developing. Doctors use different methods to disrupt the supply of chemicals that help cancer grow and cause it to deteriorate slowly. This led to the development of targeted therapy. Targeted therapy aims at various links in the tumor's supply chains (proteins, genes, receptors, etc. ) to stop it from growing further. Modern approaches for parotid gland cancer treatment with targeted therapy include many drugs, including bicalutamide, trastuzumab, leuprolide, ado-trastuzumab emtansine, and many others. Most often, targeted drugs might become a part of combined treatment and aims to reinforce other therapy types. Also, during a single course of targeted therapy, oncologists might prescribe a few medications simultaneously to strengthen the effect. A single treatment session typically takes about 2 to 4 hours. Most often, drugs are delivered via intravenous injections or droppers. Still, oral administration forms (e. g. , pills) are also available for some targeted therapy medications. To obtain sustainable effects, patients might need to undergo between 4 to 10 courses of treatment.